CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer

Hepato-Gastroenterology

Volumn 44, Issue 13, 1997, Pages 279-283

  Ishii, Hiroshi ^a   Okada, Shuichi ^a   Sato, Tosiya ^b   Wakasugi, Hideyuki ^c   Saisho, Hiromitsu ^d   Furuse, Jyunji ^e   Ishikawa, Osamu ^f   Matsuno, Seiki ^g   Yokoyama, Shinji ^h  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b INSTITUTE OF STATISTICAL MATHEMATICS   (Japan)

^c National Hospital Organization   (Japan)

^d CHIBA UNIVERSITY   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^f CENTER FOR ADULT DISEASES   (Japan)

^g TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

Author keywords

CA 19 9; Chemotherapy; Pancreatic neoplasm; Prognosis

Indexed keywords

CA 19-9 ANTIGEN; FLUOROURACIL; PYRIMIDINE ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; REGRESSION ANALYSIS; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CA-19-9 ANTIGEN; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0031056804     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Steinberg WM, Gelfand R, Anderson KK, Glenn J, Kurtzman SH, Sindelar WF, Toskes PP: Comparison of the sensitivity and specificity of the CA 19-9 and Carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology 1980; 90: 343-349.
2. Pleskow DK, Berger HJ, Gyves J, Allen E, McLean A, Podolsky DK: Evaluation of a serologic marker, CA 19-9, in the diagnosis of pancreatic cancer. Ann Int Med 1989; 110: 704-709.
3. Glenn J, Steinberg WM, Kurtzman SH, Steinberg SM, Sindelar W: Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 1988; 6: 462-468.
4. Tian F, Appert HE, Myles J, Howard JM: Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. Ann Surg 1992; 215: 350-355.
5. Yasue M, Sakamoto J, Teramukai S, Morimoto T, Yasui K, Kuno N, Kurimoto K, Ohashi Y: Prognostic values of preoperative and postoperative CEA and CA 19-9 levels in pancreatic cancer. Pancreas 1994; 9: 735-740.
6. Beretta E, Malesci A, Zerbi A, Mariani A, Carlucci M, Bonato C, Ferrari AM, DiCarlo V: Serum CA 19-9 in the postsurgical follow-up of patients with pancreatic cancer. Cancer 1987; 60: 2428-2431.
7. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
8. Cox DR: Regression models and life-tables [with discussion]. J R Stat Soc 1972; 34 [Series B]: 187-220.
9. Yamaguchi K, Enjoji M: Carcinoma of the pancreas: a clinicopathological observations. Jpn J Clin Oncol 1989; 19: 14-22.
10. Aoki K, Okada S, Moriyama N, Ishv̈ H, Nose H, Yoshimori M, Kosuge T, Ozaki H, Wakao F, Takayasu K, Mukai K: Accuracy of computed tomography in determining pancreatic cancer tumor size. Jpn J Clin Oncol 1994; 24: 85-87.
11. Wong A and Chan A: The use of the tumor marker CA 19-9 in evaluating the response to tamoxifen therapy in patients with unresectable adenocarcinoma of the pancreas. Eur J Cancer 1996; 31A: 2118-2119.